Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Italiano
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Türkçe
SGMT
#3054
Sagimet Biosciences Inc. Series A Common Stock
5.7
1
-1.04%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
-1.04%
Variazione Mensile
-6.55%
Variazione di 6 mesi
-26.04%
Variazione Annuale
+58.17%
Chiusura Precedente
5.7
7
Open
5.7
1
Bid
Ask
Low
5.7
1
High
5.7
1
Volume
21
Mercati
Mercato Azionario Statunitense
Salute
SGMT
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
2023
2024
TTM
Key stats
Total common shares outstanding
31.91 M
32.2 M
—
Valuation ratios
Enterprise value
—
—
—
Price to earnings ratio
-2
-3.1
-12.76
Price to sales ratio
27.88
—
—
Price to cash flow ratio
2.35
3.32
14.78
Price to book ratio
0.61
0.91
1.88
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
-0.29
-0.28
-0.4
Return on equity %
-0.31
-0.29
-0.42
Return on invested capital %
-108.46 K
-6 666
—
Gross margin %
100
—
—
Operating margin %
-1 537
—
—
EBITDA margin %
—
—
—
Net margin %
-1 393.8
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
17.09
34.3
85.33
Inventory turnover
—
—
—
Asset turnover
0.02
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
-2.27
-1.35
-1.4
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
9.07
5.06
17.65
Net current asset value per share
9.24
4.87
17.06
Tangible book value per share
8.71
4.97
17.02
Working capital per share
8.7
4.73
16.19
Book value per share
8.71
4.97
17.02
Notizie
Azioni Sagimet in rialzo dopo dati positivi sulla sicurezza del farmaco per l’acne
Sagimet stock rises after positive Phase 3 safety data for acne drug
Ascletis reports positive long-term safety data for acne drug denifanstat
Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market (SGMT)
Sagimet riporta risultati positivi di Fase 1 per terapia combinata contro MASH
Sagimet reports positive Phase 1 results for MASH combination therapy
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Sagimet Biosciences executive chairman sells $290k in shares
Obiettivo di prezzo di Sagimet Biosciences alzato a $35 da Citizens
Sagimet Biosciences stock price target raised to $35 by Citizens
Denifanstat raggiunge tutti gli endpoint nello studio di fase 3 sull’acne in Cina
Denifanstat meets all endpoints in phase 3 acne trial in China